Results 61 to 70 of about 101,610 (217)
Arthritis &Rheumatology, EarlyView.Objective The hematopoietic system maintains homeostasis by balancing myeloid and lymphoid cell production in the bone marrow (BM). In response to increased hematopoietic demand, extramedullary hematopoiesis (EMH) may occur in nonlymphoid organs. We investigated the role of EMH and kidney‐resident hematopoietic stem and progenitor cells (HSPCs) in ...
Hansol Yi +9 more
wiley +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Arthritis &Rheumatology, EarlyView.Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede +11 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk +5 more
wiley +1 more source
Clinical manifestations and outcomes of pediatric chronic neutropenia
Journal of the Formosan Medical Association, 2012 Neutropenia is a decrease in the number of circulating neutrophils. When neutropenia persists for more than 3 months, it becomes chronic. A heterogeneous group of diseases in children can cause chronic neutropenia.
Chuan Wan +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan +24 more
wiley +1 more source
BMEMat, EarlyView.The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang +6 more
wiley +1 more source
Modeling the Hematopoietic Landscape
Frontiers in Cell and Developmental Biology, 2019 Some time ago, we proposed a continuum-like view of the lineages open to hematopoietic stem cells (HSCs); each HSC self-renews or chooses from the spectrum of all end-cell options and can then “merely” differentiate.
Geoffrey Brown, Rhodri Ceredig
doaj +1 more source
BMEMat, EarlyView.The construct of cell‐niche co‐aggregates (GelMA‐SHED sphere‐DDMPs) promotes cranial and periodontal bone regeneration and ensures angiogenic‐osteogenic coupling by downregulating miR‐34c‐5p to enhance the expression of NOTCH1 and its intracellular domain (NICD).
Xiao‐Hui Zhang +23 more
wiley +1 more source